APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Intravitreal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-VEGF Intravitreal Drugs Market Analysis and Forecast 2026-2032

Report ID 173965500227 December 2025195 pages

Choose your research edition.

Industry ResearchAnti-VEGF Intravitreal Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Intravitreal Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Intravitreal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Intravitreal Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Intravitreal Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Anti-VEGF Intravitreal Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-VEGF Intravitreal Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-VEGF Intravitreal Drugs include Qilu Pharma, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences, Biogen and Biocon Biologics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-VEGF Intravitreal Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-VEGF Intravitreal Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-VEGF Intravitreal Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-VEGF Intravitreal Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-VEGF Intravitreal Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-VEGF Intravitreal Drugs sales, projected growth trends, production technology, application and end-user industry.

Anti-VEGF Intravitreal Drugs Segment by Company

Qilu Pharma

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biogen

Biocon Biologics

Anti-VEGF Intravitreal Drugs Segment by Type

Aflibercept

Brolucizumab

Faricimab

Conbercept

Ranibizumab

Other

Anti-VEGF Intravitreal Drugs Segment by Application

Age-related Macular Degeneration

Retinal Vein Occlusion

Diabetic Macular Edema

Other

Anti-VEGF Intravitreal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Intravitreal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Intravitreal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Intravitreal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-VEGF Intravitreal Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-VEGF Intravitreal Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGF Intravitreal Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-VEGF Intravitreal Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Aflibercept Major Manufacturers Table 3. Brolucizumab Major Manufacturers Table 4. Faricimab Major Manufacturers Table 5. Conbercept Major Manufacturers Table 6. Ranibizumab Major Manufacturers Table 7. Other Major Manufacturers Table 8. Global Anti-VEGF Intravitreal Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Age-related Macular Degeneration Major Manufacturers Table 10. Retinal Vein Occlusion Major Manufacturers Table 11. Diabetic Macular Edema Major Manufacturers Table 12. Other Major Manufacturers Table 13. Anti-VEGF Intravitreal Drugs Industry Trends Table 14. Anti-VEGF Intravitreal Drugs Industry Drivers Table 15. Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges Table 16. Anti-VEGF Intravitreal Drugs Industry Restraints Table 17. Global Anti-VEGF Intravitreal Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Anti-VEGF Intravitreal Drugs Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021-2026) Table 21. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2027-2032) Table 22. Global Anti-VEGF Intravitreal Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 23. Global Anti-VEGF Intravitreal Drugs Sales by Region (2021-2026) & (K Units) Table 24. Global Anti-VEGF Intravitreal Drugs Sales by Region (2027-2032) & (K Units) Table 25. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021-2026) Table 26. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2027-2032) Table 27. Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021-2026) Table 31. Global Anti-VEGF Intravitreal Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 32. Global Anti-VEGF Intravitreal Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Anti-VEGF Intravitreal Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Anti-VEGF Intravitreal Drugs Manufacturers, Product Type & Application Table 35. Global Anti-VEGF Intravitreal Drugs Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Anti-VEGF Intravitreal Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Anti-VEGF Intravitreal Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2026) Table 42. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2027-2032) Table 43. Global Anti-VEGF Intravitreal Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 44. Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 45. Global Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 46. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2026) Table 47. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2027-2032) Table 48. Global Anti-VEGF Intravitreal Drugs Price by Type (2021-2026) & (US$/Unit) Table 49. Global Anti-VEGF Intravitreal Drugs Price by Type (2027-2032) & (US$/Unit) Table 50. Global Anti-VEGF Intravitreal Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2026) Table 54. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2027-2032) Table 55. Global Anti-VEGF Intravitreal Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 56. Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 57. Global Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2026) Table 59. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2027-2032) Table 60. Global Anti-VEGF Intravitreal Drugs Price by Application (2021-2026) & (US$/Unit) Table 61. Global Anti-VEGF Intravitreal Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. Qilu Pharma Company Information Table 63. Qilu Pharma Business Overview Table 64. Qilu Pharma Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio Table 66. Qilu Pharma Recent Development Table 67. Chengdu Kanghong Pharmaceutical Company Information Table 68. Chengdu Kanghong Pharmaceutical Business Overview Table 69. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio Table 71. Chengdu Kanghong Pharmaceutical Recent Development Table 72. Samsung Bioepis Company Information Table 73. Samsung Bioepis Business Overview Table 74. Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio Table 76. Samsung Bioepis Recent Development Table 77. Roche Company Information Table 78. Roche Business Overview Table 79. Roche Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Roche Anti-VEGF Intravitreal Drugs Product Portfolio Table 81. Roche Recent Development Table 82. Regeneron Pharmaceuticals Company Information Table 83. Regeneron Pharmaceuticals Business Overview Table 84. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio Table 86. Regeneron Pharmaceuticals Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Novartis Anti-VEGF Intravitreal Drugs Product Portfolio Table 91. Novartis Recent Development Table 92. Coherus BioSciences Company Information Table 93. Coherus BioSciences Business Overview Table 94. Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio Table 96. Coherus BioSciences Recent Development Table 97. Biogen Company Information Table 98. Biogen Business Overview Table 99. Biogen Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Biogen Anti-VEGF Intravitreal Drugs Product Portfolio Table 101. Biogen Recent Development Table 102. Biocon Biologics Company Information Table 103. Biocon Biologics Business Overview Table 104. Biocon Biologics Anti-VEGF Intravitreal Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio Table 106. Biocon Biologics Recent Development Table 107. North America Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 110. North America Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 111. North America Anti-VEGF Intravitreal Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 112. North America Anti-VEGF Intravitreal Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 113. North America Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 116. North America Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 117. North America Anti-VEGF Intravitreal Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 118. North America Anti-VEGF Intravitreal Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 119. North America Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 123. North America Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 124. North America Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 125. North America Anti-VEGF Intravitreal Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 126. North America Anti-VEGF Intravitreal Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 127. United States Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 128. Canada Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 129. Mexico Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 130. Europe Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 133. Europe Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 134. Europe Anti-VEGF Intravitreal Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 135. Europe Anti-VEGF Intravitreal Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 136. Europe Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 139. Europe Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 140. Europe Anti-VEGF Intravitreal Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 141. Europe Anti-VEGF Intravitreal Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 142. Europe Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 146. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 147. Europe Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 148. Europe Anti-VEGF Intravitreal Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 149. Europe Anti-VEGF Intravitreal Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 150. Germany Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 151. France Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 152. U.K. Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 153. Italy Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 154. Russia Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 155. Spain Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 156. Netherlands Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 157. Switzerland Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 158. Sweden Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 159. Poland Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 160. China Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 161. China Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 162. China Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 163. China Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 164. China Anti-VEGF Intravitreal Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 165. China Anti-VEGF Intravitreal Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 166. China Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. China Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. China Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 169. China Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 170. China Anti-VEGF Intravitreal Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 171. China Anti-VEGF Intravitreal Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 172. Asia Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 175. Asia Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 176. Asia Anti-VEGF Intravitreal Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 177. Asia Anti-VEGF Intravitreal Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 178. Asia Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 179. Asia Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 180. Asia Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 181. Asia Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 182. Asia Anti-VEGF Intravitreal Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 183. Asia Anti-VEGF Intravitreal Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Asia Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 188. Asia Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 189. Asia Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 190. Asia Anti-VEGF Intravitreal Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 191. Asia Anti-VEGF Intravitreal Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 192. Japan Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 193. South Korea Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 194. India Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 195. Australia Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 196. Taiwan Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 198. SAMEA Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA Anti-VEGF Intravitreal Drugs Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA Anti-VEGF Intravitreal Drugs Sales by Type (2021-2026) & (K Units) Table 201. SAMEA Anti-VEGF Intravitreal Drugs Sales by Type (2027-2032) & (K Units) Table 202. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 203. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 204. SAMEA Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2026) & (US$ Million) Table 205. SAMEA Anti-VEGF Intravitreal Drugs Revenue by Application (2027-2032) & (US$ Million) Table 206. SAMEA Anti-VEGF Intravitreal Drugs Sales by Application (2021-2026) & (K Units) Table 207. SAMEA Anti-VEGF Intravitreal Drugs Sales by Application (2027-2032) & (K Units) Table 208. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 209. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 210. SAMEA Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 214. SAMEA Anti-VEGF Intravitreal Drugs Sales by Country (2021-2026) & (K Units) Table 215. SAMEA Anti-VEGF Intravitreal Drugs Sales by Country (2027-2032) & (K Units) Table 216. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 217. SAMEA Anti-VEGF Intravitreal Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 218. Brazil Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 219. Argentina Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 220. Chile Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 221. Colombia Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 222. Peru Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 224. Israel Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 225. UAE Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 226. Turkey Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 227. Iran Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 228. Egypt Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Anti-VEGF Intravitreal Drugs Distributors List Table 232. Anti-VEGF Intravitreal Drugs Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Anti-VEGF Intravitreal Drugs Image Figure 2. Global Anti-VEGF Intravitreal Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Intravitreal Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Aflibercept Image Figure 5. Brolucizumab Image Figure 6. Faricimab Image Figure 7. Conbercept Image Figure 8. Ranibizumab Image Figure 9. Other Image Figure 10. Global Anti-VEGF Intravitreal Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Anti-VEGF Intravitreal Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 12. Age-related Macular Degeneration Image Figure 13. Retinal Vein Occlusion Image Figure 14. Diabetic Macular Edema Image Figure 15. Other Image Figure 16. Global Anti-VEGF Intravitreal Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Anti-VEGF Intravitreal Drugs Revenue (2021-2032) & (US$ Million) Figure 18. Global Anti-VEGF Intravitreal Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021-2032) Figure 21. Global Anti-VEGF Intravitreal Drugs Sales (2021-2032) & (K Units) Figure 22. Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 23. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Anti-VEGF Intravitreal Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Europe Anti-VEGF Intravitreal Drugs Sales YoY (2021-2032) & (K Units) Figure 26. China Anti-VEGF Intravitreal Drugs Sales YoY (2021-2032) & (K Units) Figure 27. Asia (Excluding China) Anti-VEGF Intravitreal Drugs Sales YoY (2021-2032) & (K Units) Figure 28. South America, Middle East and Africa Anti-VEGF Intravitreal Drugs Sales YoY (2021-2032) & (K Units) Figure 29. Global Anti-VEGF Intravitreal Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Anti-VEGF Intravitreal Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2032) Figure 35. Global Anti-VEGF Intravitreal Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2032) Figure 38. Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032) Figure 41. Global Anti-VEGF Intravitreal Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 42. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2032) Figure 44. North America Anti-VEGF Intravitreal Drugs Revenue Share by Type (2021-2032) Figure 45. North America Anti-VEGF Intravitreal Drugs Sales Share by Type (2021-2032) Figure 46. North America Anti-VEGF Intravitreal Drugs Revenue Share by Application (2021-2032) Figure 47. North America Anti-VEGF Intravitreal Drugs Sales Share by Application (2021-2032) Figure 48. North America Anti-VEGF Intravitreal Drugs Revenue Share by Country (2021-2032) Figure 49. North America Anti-VEGF Intravitreal Drugs Sales Share by Country (2021-2032) Figure 50. Europe Anti-VEGF Intravitreal Drugs Revenue Share by Type (2021-2032) Figure 51. Europe Anti-VEGF Intravitreal Drugs Sales Share by Type (2021-2032) Figure 52. Europe Anti-VEGF Intravitreal Drugs Revenue Share by Application (2021-2032) Figure 53. Europe Anti-VEGF Intravitreal Drugs Sales Share by Application (2021-2032) Figure 54. Europe Anti-VEGF Intravitreal Drugs Revenue Share by Country (2021-2032) Figure 55. Europe Anti-VEGF Intravitreal Drugs Sales Share by Country (2021-2032) Figure 56. China Anti-VEGF Intravitreal Drugs Revenue Share by Type (2021-2032) Figure 57. China Anti-VEGF Intravitreal Drugs Sales Share by Type (2021-2032) Figure 58. China Anti-VEGF Intravitreal Drugs Revenue Share by Application (2021-2032) Figure 59. China Anti-VEGF Intravitreal Drugs Sales Share by Application (2021-2032) Figure 60. Asia Anti-VEGF Intravitreal Drugs Revenue Share by Type (2021-2032) Figure 61. Asia Anti-VEGF Intravitreal Drugs Sales Share by Type (2021-2032) Figure 62. Asia Anti-VEGF Intravitreal Drugs Revenue Share by Application (2021-2032) Figure 63. Asia Anti-VEGF Intravitreal Drugs Sales Share by Application (2021-2032) Figure 64. Asia Anti-VEGF Intravitreal Drugs Revenue Share by Country (2021-2032) Figure 65. Asia Anti-VEGF Intravitreal Drugs Sales Share by Country (2021-2032) Figure 66. SAMEA Anti-VEGF Intravitreal Drugs Revenue Share by Type (2021-2032) Figure 67. SAMEA Anti-VEGF Intravitreal Drugs Sales Share by Type (2021-2032) Figure 68. SAMEA Anti-VEGF Intravitreal Drugs Revenue Share by Application (2021-2032) Figure 69. SAMEA Anti-VEGF Intravitreal Drugs Sales Share by Application (2021-2032) Figure 70. SAMEA Anti-VEGF Intravitreal Drugs Revenue Share by Country (2021-2032) Figure 71. SAMEA Anti-VEGF Intravitreal Drugs Sales Share by Country (2021-2032) Figure 72. Anti-VEGF Intravitreal Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Anti-VEGF Intravitreal Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Aflibercept
  • Brolucizumab
  • Faricimab
  • Conbercept
  • Ranibizumab
  • Other
Applications
  • Age-related Macular Degeneration
  • Retinal Vein Occlusion
  • Diabetic Macular Edema
  • Other
Companies covered
  • Qilu Pharma
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biogen
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-VEGF Intravitreal Drugs Market by Type
  3. 1.2.1 Global Anti-VEGF Intravitreal Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Aflibercept
  5. 1.2.3 Brolucizumab
  6. 1.2.4 Faricimab
  7. 1.2.5 Conbercept
  8. 1.2.6 Ranibizumab
  9. 1.2.7 Other
  10. 1.3 Anti-VEGF Intravitreal Drugs Market by Application
  11. 1.3.1 Global Anti-VEGF Intravitreal Drugs Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Age-related Macular Degeneration
  13. 1.3.3 Retinal Vein Occlusion
  14. 1.3.4 Diabetic Macular Edema
  15. 1.3.5 Other
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Anti-VEGF Intravitreal Drugs Market Dynamics
  1. 2.1 Anti-VEGF Intravitreal Drugs Industry Trends
  2. 2.2 Anti-VEGF Intravitreal Drugs Industry Drivers
  3. 2.3 Anti-VEGF Intravitreal Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Intravitreal Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-VEGF Intravitreal Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region
  3. 3.2.1 Global Anti-VEGF Intravitreal Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-VEGF Intravitreal Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-VEGF Intravitreal Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-VEGF Intravitreal Drugs Sales by Region
  9. 3.4.1 Global Anti-VEGF Intravitreal Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-VEGF Intravitreal Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-VEGF Intravitreal Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers
  2. 4.1.1 Global Anti-VEGF Intravitreal Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-VEGF Intravitreal Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers
  6. 4.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-VEGF Intravitreal Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-VEGF Intravitreal Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-VEGF Intravitreal Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-VEGF Intravitreal Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-VEGF Intravitreal Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Anti-VEGF Intravitreal Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-VEGF Intravitreal Drugs Market CR5 and HHI
  16. 4.8.2 2025 Anti-VEGF Intravitreal Drugs Tier 1, Tier 2, and Tier 3
5 Anti-VEGF Intravitreal Drugs Market by Type
  1. 5.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type
  2. 5.1.1 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-VEGF Intravitreal Drugs Sales by Type
  6. 5.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-VEGF Intravitreal Drugs Price by Type
6 Anti-VEGF Intravitreal Drugs Market by Application
  1. 6.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application
  2. 6.1.1 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-VEGF Intravitreal Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-VEGF Intravitreal Drugs Sales by Application
  6. 6.2.1 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Anti-VEGF Intravitreal Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-VEGF Intravitreal Drugs Price by Application
7 Company Profiles
  1. 7.1 Qilu Pharma
  2. 7.1.1 Qilu Pharma Company Information
  3. 7.1.2 Qilu Pharma Business Overview
  4. 7.1.3 Qilu Pharma Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Qilu Pharma Anti-VEGF Intravitreal Drugs Product Portfolio
  6. 7.1.5 Qilu Pharma Recent Developments
  7. 7.2 Chengdu Kanghong Pharmaceutical
  8. 7.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 7.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 7.2.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Intravitreal Drugs Product Portfolio
  12. 7.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 7.3 Samsung Bioepis
  14. 7.3.1 Samsung Bioepis Company Information
  15. 7.3.2 Samsung Bioepis Business Overview
  16. 7.3.3 Samsung Bioepis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Samsung Bioepis Anti-VEGF Intravitreal Drugs Product Portfolio
  18. 7.3.5 Samsung Bioepis Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Roche Anti-VEGF Intravitreal Drugs Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Regeneron Pharmaceuticals
  26. 7.5.1 Regeneron Pharmaceuticals Company Information
  27. 7.5.2 Regeneron Pharmaceuticals Business Overview
  28. 7.5.3 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Regeneron Pharmaceuticals Anti-VEGF Intravitreal Drugs Product Portfolio
  30. 7.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Anti-VEGF Intravitreal Drugs Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Coherus BioSciences
  38. 7.7.1 Coherus BioSciences Company Information
  39. 7.7.2 Coherus BioSciences Business Overview
  40. 7.7.3 Coherus BioSciences Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Coherus BioSciences Anti-VEGF Intravitreal Drugs Product Portfolio
  42. 7.7.5 Coherus BioSciences Recent Developments
  43. 7.8 Biogen
  44. 7.8.1 Biogen Company Information
  45. 7.8.2 Biogen Business Overview
  46. 7.8.3 Biogen Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Biogen Anti-VEGF Intravitreal Drugs Product Portfolio
  48. 7.8.5 Biogen Recent Developments
  49. 7.9 Biocon Biologics
  50. 7.9.1 Biocon Biologics Company Information
  51. 7.9.2 Biocon Biologics Business Overview
  52. 7.9.3 Biocon Biologics Anti-VEGF Intravitreal Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Biocon Biologics Anti-VEGF Intravitreal Drugs Product Portfolio
  54. 7.9.5 Biocon Biologics Recent Developments
8 North America
  1. 8.1 North America Anti-VEGF Intravitreal Drugs Market Size by Type
  2. 8.1.1 North America Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
  5. 8.2 North America Anti-VEGF Intravitreal Drugs Market Size by Application
  6. 8.2.1 North America Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
  9. 8.3 North America Anti-VEGF Intravitreal Drugs Market Size by Country
  10. 8.3.1 North America Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-VEGF Intravitreal Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-VEGF Intravitreal Drugs Market Size by Type
  2. 9.1.1 Europe Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
  5. 9.2 Europe Anti-VEGF Intravitreal Drugs Market Size by Application
  6. 9.2.1 Europe Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
  9. 9.3 Europe Anti-VEGF Intravitreal Drugs Market Size by Country
  10. 9.3.1 Europe Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-VEGF Intravitreal Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-VEGF Intravitreal Drugs Market Size by Type
  2. 10.1.1 China Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
  5. 10.2 China Anti-VEGF Intravitreal Drugs Market Size by Application
  6. 10.2.1 China Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-VEGF Intravitreal Drugs Market Size by Type
  2. 11.1.1 Asia Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
  5. 11.2 Asia Anti-VEGF Intravitreal Drugs Market Size by Application
  6. 11.2.1 Asia Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
  9. 11.3 Asia Anti-VEGF Intravitreal Drugs Market Size by Country
  10. 11.3.1 Asia Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-VEGF Intravitreal Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-VEGF Intravitreal Drugs Market Size by Type
  2. 12.1.1 SAMEA Anti-VEGF Intravitreal Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-VEGF Intravitreal Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-VEGF Intravitreal Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-VEGF Intravitreal Drugs Market Size by Application
  6. 12.2.1 SAMEA Anti-VEGF Intravitreal Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-VEGF Intravitreal Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-VEGF Intravitreal Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-VEGF Intravitreal Drugs Market Size by Country
  10. 12.3.1 SAMEA Anti-VEGF Intravitreal Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-VEGF Intravitreal Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-VEGF Intravitreal Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-VEGF Intravitreal Drugs Value Chain Analysis
  2. 13.1.1 Anti-VEGF Intravitreal Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-VEGF Intravitreal Drugs Production Mode & Process
  6. 13.2 Anti-VEGF Intravitreal Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-VEGF Intravitreal Drugs Distributors
  9. 13.2.3 Anti-VEGF Intravitreal Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst